Volume 3.46 | Nov 24

Human Immunology News 3.46 November 24, 2015
Human Immunology News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  HIN on Twitter
Measuring Immune Cells before Surgery May Help Predict Recovery Time
The behavior of a type of white blood cell can indicate how soon patients will be back on their feet after hip surgery. Blood drawn an hour before surgery and stimulated to produce an immune response revealed patterns that predict patient health outcomes. [Press release from Stanford University School of Medicine discussing online prepublication in Anesthesiology] Press Release | Abstract
New Cell Separation Kits to Isolate 90% Pure CD34+ Cells from Cord Blood. See the data and learn more here!
PUBLICATIONS (Ranked by impact factor of the journal)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T Cell Trafficking in Colon Cancer
Scientists found that polycomb repressive complex 2 (PRC2) components and demethylase JMJD3-mediated histone H3 lysine 27 trimethylation repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, mediators of effector T cell trafficking. [Cancer Res] Abstract

T-Cell Receptor-HLA-DRB1 Associations Suggest Specific Antigens in Pulmonary Sarcoidosis
To investigate T-cell receptor-HLA-DRB1*03 interactions underlying recognition of hitherto unknown antigens, researchers performed detailed analyses of T-cell receptor expression on bronchoalveolar lavage fluid CD4+ T-cells from sarcoidosis patients. [Eur Respir J] Abstract

Lamina Propria CD4+LAP+ Regulatory T Cells Are Increased in Active Ulcerative Colitis but Show Increased IL-17 Expression and Reduced Suppressor Activity
The authors investigated the frequency and function of lamina propria (LP) CD4+LAP+ T cells in inflammatory bowel disease patients. LP CD3+CD8LAP+ cells were significantly increased, when compared to controls, in active ulcerative colitis patients and not in Crohn’s disease patients. [J Crohns Colitis] Abstract

MicroRNA-155-IFN-γ Feedback Loop in CD4+ T Cells of Erosive Type Oral Lichen Planus
Researchers determined the role of miR-155 in immune response of oral lichen planus (OLP) and determined the expression and correlation of microRNA-155 and SOCS1 in erosive-type OLP CD4+ T cells. [Sci Rep] Full Article

Anti-Inflammatory Activity of Low Molecular Weight Polysialic Acid on Human Macrophages
Scientists showed that soluble low molecular weight polysialic acid with an average degree of polymerization 20 interacts with sialic acid-binding immunoglobulin-like lectin-11 (SIGLEC-11) and acts anti-inflammatory on human THP1 macrophages involving the SIGLEC-11 receptor. [Sci Rep] Full Article

Alternative Promoter Methylation Regulates Together with Foxp3 Transcription of GARP
Investigators report that transcription of human glycoprotein A repetitions predominant (GARP) in regulatory CD4 T cells is tightly regulated by two alternative promoters. [Biochim Biophys Acta] Abstract

Immunomodulation of Endothelial Differentiated Mesenchymal Stromal Cells: Impact on T and NK Cells
The authors sought to determine the impact of differentiation toward endothelial cells on immunoregulation by Wharton’s jelly mesenchymal stromal cells (WJ-MSCs). They co-cultured un- and differentiated MSCs with immune cells, under conditions of both direct and indirect contact. [Immunol Cell Biol] Abstract

Evidence for Epigenetic Regulation of Pro-Inflammatory Cytokines, Interleukin-12 and Interferon Gamma, in Peripheral Blood Mononuclear Cells from PTSD Patients
Investigators examined genome-wide histone and DNA methylation in the peripheral blood mononuclear cells (PBMCs) in post traumatic stress disorder (PTSD). PTSD patients showed increased expression of interleukin (IL)-12 in their PBMCs. [J Neuroimmune Pharmacol] Abstract

Processing and MHC Class II Presentation of Exogenous Soluble Antigen Involving a Proteasome-Dependent Cytosolic Pathway in CD40-Activated B Cells
Scientists investigated the MHC class II processing pathway in CD40-activated B cells (CD40Bs), as a model for activated, antigen-presenting B cells. Using CMV pp65 as a model antigen, they evaluated processing and presentation of the CD4+ T cell epitope 509-523 by human CD40Bs in Elispot assays. [Eur J Haematol] Abstract

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Isolate Immune Cells from Whole Blood without Lysis or Centrifugation with EasySep™ Direct. Request a Free Sample!
NK-92: An ‘Off-the-Shelf Therapeutic’ for Adoptive Natural Killer Cell-Based Cancer Immunotherapy
The concept of a natural killer (NK) cell line as an allogeneic cell therapeutic produced ‘off-the-shelf’ on demand holds great promise for the development of effective treatments. [Cancer Immunol Immunother] Abstract

Toll-Like Receptors: Potential Targets for Lupus Treatment
Numerous antagonists targeting Toll-like receptor signaling, including oligonucleotides, small molecular inhibitors and antibodies, are currently under preclinical studies or clinical trials for systemic lupus erythematosus treatment. [Acta Pharmacol Sin] Full Article

Visit our reviews page to see a complete list of reviews in the Human Immunology research field.
VBI Vaccines Presents Update and New Data Supporting Its Glioblastoma Immunotherapy Program
VBI Vaccines Inc. presented an update and new data supporting its glioblastoma multiforme cancer immunotherapy program. [Press release from VBI Vaccines Inc. discussing research presented at the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology 2015, Lausanne]
Press Release | Poster

Combination of Bevacizumab and Lomustine with First Recurrence of Glioblastoma Prolongs PFS but Not OS
Results of EORTC trial 26101 showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage. [Press release from the European Organisation for Research and Treatment of Cancer (EORTC) discussing research presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), San Antonio] Press Release

Long-Term Survival Benefit Demonstrated in Phase II ReACT Study of RINTEGA® in Recurrent Bevacizumab-Naive Glioblastoma
Celldex Therapeutics, Inc. presented mature survival data from the company’s randomized, double-blind Phase II study of RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma. [Press release from Celldex Therapeutics, Inc. discussing research presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), San Antonio] Press Release

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Survival and Immune Response Data
ImmunoCellular Therapeutics, Ltd. announced the presentation of recently updated overall survival results and immune response data from the Phase II trial of ICT-107 in patients with newly diagnosed glioblastoma. [Press release from ImmunoCellular Therapeutics, Ltd. discussing research presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), San Antonio] Press Release

Merck Announces Initial Results for KEYTRUDA® (Pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented
Merck announced findings from three studies investigating the use of KEYTRUDA®, the company’s anti-PD-1 therapy, in combination with three other immunotherapies – epacadostat, IMLYGICTM, and ipilimumab – in patients with advanced melanoma. [Press release from Merck & Co., Inc. discussing research presented at the 12th International Congress of the Society for Melanoma Research (SMR), San Francisco] Press Release

From our sponsor:
Working with blood? Look up human blood cell frequencies quickly. Request your free wallchart.
Funding for Promising Vaccine to Shrink Tumors
Professor Bruce Robinson believes his team is close to developing a vaccine to try and shrink cancerous tumors. The National Health and Medical Research Council has given a $2.5 million Centers of Research Excellence grant to advance the research. [The University of Western Australia] Press Release

City of Hope Clinical Trial Will Test Cancer Vaccine with Anti-Tumor Drug
In a clinical trial to be launched at City of Hope in November, researchers will combine two approaches — an immune-boosting vaccine and a drug that blocks a tumor’s inhibitory signal — to more effectively activate a patient’s own immune system to fight his or her cancer. [City of Hope (Newswise, Inc.)] Press Release

FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer
The U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to treat patients with advanced renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. [U.S. Food and Drug Administration] Press Release

Nivolumab in Non-Small Cell Lung Cancer: Indication of Major Added Benefit for Under-75-Year-Olds
The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether nivolumab offers an added benefit over the appropriate comparator therapy in the treatment of non-small cell lung cancer . [Institute for Quality and Efficiency in Health Care] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposium – Cell Biology and Immunology of Persistent Infection
January 31-February 4, 2016
Banff, Canada

Visit our events page to see a complete list of events in the Human Immunology community.
NEW Postdoctoral Researcher – Cancer Immunotherapy (University College Cork)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Research Technician – Preclinical and Translational Research (Qu Biologics Inc.)

Postdoctoral Fellow – Immunology (Medical College of Wisconsin)

Postdoctoral Fellow – Transplantation Immunology (H. Lee Moffitt Cancer Center & Research Institute)

Assistant Professor – Cancer Immunology (Children’s Hospital of Philadelphia)

Postdoctoral Position – Immunology and Cell Biology (Beth Israel Deaconess Medical Center)

Staff Scientist – Immunology (Benaroya Research Institute at Virginia Mason)

Postdoctoral Research Fellow – Molecular Oncology (Genentech, Inc.)

Professor – Immunology (La Jolla Institute for Allergy & Immunology)

Principal Investigator – The Role of Inflammation and the Immune Response in Regenerative Medicine (KU Leuven)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us